Florian Lordick, Professor of Medicine at University of Leipzig, shared a post on LinkedIn:
“Matterhorn study on perioperative immune chemotherapy in resectable Gastric Adenocarcinoma.
Overall survival data presented at ESMO Berlin2025 congress.
Classification of data in clinical practice.”
You can also read: MATTERHORN Trial at ESMO 2025: Durvalumab Plus FLOT in Resectable Gastric and GEJ Adenocarcinoma
